Results 91 to 100 of about 72,717 (274)
World Journal of Surgical Oncology, 2018 BackgroundDenosumab has been shown to reduce tumor size and progression, reform mineralized bone, and increase intralesional bone density in patients with giant cell tumor of bone (GCTB); however, radiologic assessment of tumors in bone is challenging ...
J. Engellau +13 more
semanticscholar +1 more source
Giant-cell tumor of the patella: An uncommon cause of fracture
Archives of Clinical and Experimental Surgery, 2017 Primary patellar tumors are highly unusual. Most are benign neoplasms with giant-cell tumors being the most common, followed by chondroblastomas and aneurysmal bone cysts.
Esther Carbó-Laso +6 more
doaj +1 more source
, 2013 67-year-old female who was referred from her general practitioner because of uncontrolled right popliteal knee pain which was very severe and continuously deteriorating. She could not bend her knee and sleep because of the pain.
Bertuello, Isaac, Bonnici, Maria
core
Systematic review and meta-analysis of en bloc vertebrectomy compared with intralesional resection for giant cell tumors of the mobile spine [PDF]
, 2016 Study Design Systematic review and meta-analysis. Objective To compare the recurrence and perioperative complication rate of en bloc vertebrectomy (EV) and intralesional resection (IR) in the giant cell tumor of the mobile spine (SGCT).
Buchowski, Jacob M +3 more
core +2 more sources
Excessive growth hormone expression in male GH transgenic mice adversely alters bone architecture and mechanical strength [PDF]
, 2015 Patients with acromegaly have a higher prevalence of vertebral fractures despite normal bone mineral density (BMD), suggesting that GH overexpression has adverse effects on skeletal architecture and strength. We used giant bovine GH (bGH) transgenic mice
Chavassieux, P +10 more
core +4 more sources
A recurrent giant cell tumor of bone treated with denosumab
Clinics and Practice, 2015 Although the giant cell tumor of bone is generally classified as a benign tumor it can rarely metastasize and has a potential risk of local recurrence. We want to report about a female patient who suffered from a recurrence of a giant cell tumor of bone ...
Nicola Stadler +3 more
doaj +1 more source
Insight into the pathogenesis and nature of Central giant cell lesions of the jaws [PDF]
, 2015 Central giant cell lesions of the jaws are not uncommon. While the majority of these represent single, sporadic lesions, histologically identical lesions are seen in association with a number of other bone lesions, as well as in certain syndromes. This
Edwards, Paul Charles
core +3 more sources
Short‐term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone
Orthopaedic Surgery, 2019 The purpose of this retrospective study was to evaluate the clinical and oncological results of combination treatment of short‐term preoperative denosumab (the receptor activator of nuclear factor kappa‐B ligand inhibitor) with surgery in unresectable or
Runzi Zhang +5 more
semanticscholar +1 more source
Clinical Orthopaedics and Related Research, 2019 BACKGROUND Denosumab, a monoclonal antibody that binds to receptor activation of nuclear factor-kappa ß ligand (RANKL), has been used as a drug to treat aggressive giant cell tumors of bone.
S. Tsukamoto +5 more
semanticscholar +1 more source